Transgene Announces Positive Interim Analysis Results of Pha

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of

Related Keywords

Germany , United States , Ankara , Turkey , United Kingdom , France , Spain , Lucie Larguier , Christophe Le Tourneau , Le Tourneau , Ben Brahim , Transgene Euronext , Sylvie Berrebi George Underwood , Maud Brandely , Head Of The Department Drug Development , Twitter , Data Monitoring Committee , Curie Institute , Pfizer , Astrazeneca , Merck Kga , Pfizer Inc , Corporate Communications , Merck Kgaa , Euronext Paris , Independent Data Monitoring Committee , Chief Medical Officer , Hedi Ben Brahim , Chief Executive Officer , Modified Vaccinia Ankara , Drug Development , Principal Investigator , Artificial Intelligence , Risk Factors , Universal Registration Document , Human Papilloma Virus , Human Papillomavirus , Transgene , Nnounces , Positive , Interim , Analysis , Results , Hase , Trial , Valuating , Tg4001 , Avelumab , Anogenital , Cancers ,